177Lu-Vipivotide Tetraxetan (177Lu-PSMA-617, Pluvicto) Therapy

被引：1
|
作者：
Clements, Sarah
Tempesta, Daniel
Jacene, Heather
机构：
来源：
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY | 2022年 / 50卷 / 03期
关键词：
D O I：
10.2967/jnmt.122.264731
中图分类号：
R8 [特种医学]; R445 [影像诊断学];
学科分类号：
1002 ; 100207 ; 1009 ;
摘要：
[No abstract available]
引用
收藏
页码：213 / 214
页数：2
相关论文
共 50 条
  • [41] Reducing Lu 177-Vipivotide Tetraxetan (PSMA) Acquisition Time While Maintaining Spatial Resolution
    Alsarag, Leila
    Bajric, Ejda
    Broska, Hailey
    Frye, Sarah
    Botkin, Crystal
    Osman, Medhat
    JOURNAL OF NUCLEAR MEDICINE, 2023, 64
  • [42] Survey of Clinical Protocols for the Use of 177Lu-PSMA-617 in the United States
    Kuo, Phillip H.
    Covington, Matthew F.
    Lee, Daniel J.
    Wong, Terence Z.
    Pandit-Taskar, Neeta
    JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY, 2024, 52 (03) : 208 - 211
  • [43] 177Lu-PSMA-617 Therapy in a Case of Metastatic Castration-Resistant Prostate Cancer
    Qu, Gengcuo
    Hua, Qingchu
    Li, Hongmei
    Zhang, Yu
    Chen, Yue
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (02) : 152 - 153
  • [44] Whole-Body Dosimetry in Therapy of Metastatic Prostate Cancer with 177Lu-PSMA-617
    Happel, C.
    Voeller, L.
    Kranert, W. T.
    Groener, D.
    Bockisch, B.
    Mader, N.
    Gruenwald, F.
    Sabet, A.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2020, 47 (SUPPL 1) : S695 - S695
  • [45] 177Lu-PSMA-617 radioligand therapy for a patient with lymph node metastatic prostate cancer
    von Eyben, Finn E.
    Kiljunen, Timo
    Joensuu, Timo
    Kairemo, Kalevi
    Uprimny, Christian
    Virgolini, Irene
    ONCOTARGET, 2017, 8 (39) : 66112 - 66116
  • [46] Value of Post-Therapy Quantitative SPECT for Monitoring Response to 177Lu-PSMA-617 Therapy
    Meyer, Catherine
    Yilmaz, Burcak
    Szidonya, Laszlo
    Winters, Celeste
    Mench, Anna
    Mallak, Nadine
    Mittra, Erik
    JOURNAL OF NUCLEAR MEDICINE, 2024, 65
  • [47] 177Lu-PSMA-617 for metastatic prostate cancer: aiming for the right spot
    Mateo, Joaquin
    Zurita, Amado J.
    LANCET, 2024, 404 (10459): : 1174 - 1176
  • [48] Does Pre-Therapy PSA Influence 177Lu-PSMA-617 Treatment Outcomes?
    Fermawi, S.
    Buehner, T.
    Kalarn, S.
    Sabottke, C.
    Recio-Boiles, A.
    Savir-Baruch, B.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2024, 51 : S363 - S363
  • [49] 177Lu-PSMA-617 Radioligand Therapy in Patient With Prostate Cancer Sciatic Nerve Metastasis
    Tonnelet, David
    Edet-Sanson, Agathe
    Augusto, Laetitia
    Cabourg, Marine
    Thureau, Sebastien
    CLINICAL NUCLEAR MEDICINE, 2024, 49 (12) : E668 - E669
  • [50] Hematotoxicity after Radioligand Therapy with 177Lu-PSMA-617 in Patients with Metastastic Prostate Cancer
    Groener, Daniel
    Baumgarten, Justus
    Davis, Karen
    Happel, Christian
    Ngoc, Christina Nguyen
    Wichert, Jennifer
    Mader, Nicolai
    Mandel, Philipp
    Nikolaos, Tselis
    Gruenwald, Frank
    Sabet, Amir
    JOURNAL OF NUCLEAR MEDICINE, 2020, 61
12345